Australia outlines roles and duties of IVD sponsors and manufacturers
This article was originally published in RAJ Devices
Australia's Therapeutic Goods Administration has issued more details on the conformity assessment process under its new in vitro diagnostics regulations that came into force in July last year1-3. Specifically, the TGA has published documents distinguishing between the responsibilities and obligations of IVD sponsors and manufacturers under the new framework.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-two guidance documents have been posted on the tracker since its last update.
Italian medicines agency chief Nicola Magrini recounts the problems AIFA faced and the lessons it learned through its work at the height of the coronavirus outbreak in Italy.
EU guidance offers high-level recommendations on the steps that clinical trial sponsors should take to assess the impact of COVID-19 on the quality and reliability of data being generated in ongoing studies. Early scientific advice is recommended if changes must be made to existing protocols or data analysis plans.